CRISPR Therapeutics AG - Common Shares (CRSP)

These stocks have market caps of around $4 billion and $5 billion, and they could potentially double or triple in size in the long run.

Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of mixed topline results from its pivotal RISE UP Phase 3 trial for mitapivat in sickle cell disease (SCD). While the investigational therapy

These stocks both have advanced in the double-digits in recent months.

This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy?

The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the nascent power of quantum computing and the burgeoning might of renewable energy, these innovations are not merely incremental improvements; they are

ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried?

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform.

The companies are working on one-and-done treatments for diseases tied to genetic problems.

The company remains confident in its other gene-editing product, which would treat a swelling disorder.

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as the linchpin in the quest to develop cures for a myriad of debilitating diseases. This significant investment is poised to revolutionize how scientists approach genetic disorders, moving beyond [...]

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam Therapeutics.

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central theme at the recent Quarter Century Update conference, where leading experts like Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, illuminated how AI is [...]

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.

These companies' market-beating fuel hasn't run out yet.

CRISPR Therapeutics is a promising mid-cap biotech stock with an approved product in its portfolio.

Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the time. Every now and then, though, the right opportunity comes along.

As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.

These biotechs could finally come into their own by the end of the decade.

As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for sustainability. This dynamic landscape is giving rise to several high-growth sectors that are not only reshaping industries but also presenting unprecedented investment opportunities.

Air taxis, quantum computing, and gene editing are all promising technologies to invest in for the long haul.

These stocks could see growth take off over the next few years.